Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.
about
Viral hepatitis and hepatocellular carcinomaHepatitis C: a review for primary care physiciansTargeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patientsAsian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis.Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma.Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylationsHeterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIα in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma.Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits.APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review.Management of chronic hepatitis C.Unnecessary repeat requesting of tests: an audit in a government hospital immunology laboratoryUsefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma.Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development.Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in PatientsHepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C.An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer.Serum biomarkers identification by mass spectrometry in high-mortality tumors.Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma.Use of Biomarkers in Screening for Cancer.Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinomaSurveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversiesDiagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors.Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm.Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity.Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma.A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers.In vivo and in vitro effect of hepatocarcinoma lymph node metastasis by upregulation of Annexin A7 and relevant mechanisms.Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems.The Presence of Portal Vein Thrombosis Alters the Classic Enhancement Associated with Diagnosis of Hepatocellular Carcinoma.The optimal follow-up period in patients with above 5-year disease-free survival after curative liver resection for hepatocellular carcinomaPrediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method.The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies.Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein.
P2860
Q21245597-570D2CEA-267F-45D9-B9B2-2317A69B6F0FQ22306040-B6B706B2-8C3F-45D6-8C35-316B5F27607FQ28085015-96CCA0FA-5DD7-4DA7-9A32-D9AF5B418BEBQ30479629-A276E22B-F54C-4B7F-A808-FA4B0B363C38Q33272872-F0C7A36C-8733-44E4-B4D2-7F3409A016F3Q33493776-6EB7913C-E2D9-4011-9E72-3228137414ABQ33728371-D4989881-A13C-44E0-B675-221D36E9EA66Q34325161-19D6B99F-A391-49CC-A686-E930CBDE47EAQ34461237-5EE0AC75-05FA-411A-935D-0933160BFAB7Q34660116-80F55CAA-6617-463A-9BAB-317859ABC78AQ34979196-1B6C2FEB-81DA-4920-87E0-9B6AC8A1AE7BQ35010543-81767CFE-5BEA-4A68-A892-823F8A426191Q35207736-0C4443F2-9852-4676-AA3F-0CDB69676218Q35522138-812ACFE2-A8C1-476D-A2EB-296796F864B5Q35588517-8DB517D6-5759-45EB-ACA2-18C47912D553Q35633563-9D1AB289-7BCC-493E-BA62-D22CB4ADF13FQ36033548-0FB4DDCD-25B3-482B-AB5B-7686A4F5E34FQ36194266-96157AD5-2EC3-4568-9848-BE9DCD8685FDQ36459759-A692421B-62C6-40DB-81EC-EE0652277916Q36476387-F355B54C-FEC9-4CAF-B582-FC44AC23A226Q36582422-BBE59ACF-4000-4F77-B8E9-B3D1DCA73E92Q36731844-FEB3761F-A074-4634-869A-31E9E8864A76Q37155019-772C232A-7DE9-4534-B57C-F8048A50F0A5Q37235449-65064A6F-9E8E-4DD9-A970-6780F7C1DDB7Q37246570-F8BED5EC-083E-465A-88E4-99FA110AE254Q37266376-26F9279E-6A4E-4A80-9E32-7F811409B357Q37577551-7D1F00C5-E6AF-42A7-AB99-A505D941E285Q37724875-A2E8C7F6-3A26-49F7-8DD2-D11054F61CE9Q38279464-3C6862CD-5D9B-49DC-9423-70ED2B2F516EQ38482765-05CBB04A-9777-4DDD-A97E-E2E1C86E297FQ38560093-2619FA33-699E-4311-9FBC-CD45394F6577Q38686490-0DD0B784-9E0D-4157-9AC1-1DB066D78F23Q38845150-9039E3CF-CB44-405B-A60B-528837D6F75EQ38883230-8CCF7868-F956-4715-8CEC-6F38FDCCD43CQ41208415-CCA4600B-8112-4F74-9463-1314958E06B3Q42783674-EA3432F7-EFA2-4B3F-989E-409EA07741F4Q42954755-A231F8A6-CA5E-4507-9DEC-6CD6D0507472Q43108443-7DD6DCDA-E1F7-4848-A849-2F49865E74FDQ43806466-AAF6A632-BC78-4D40-AE38-D63DEF128A52Q44930583-0605CCB5-B5AD-4900-9694-CFFBA414A3CE
P2860
Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Screening tests for hepatocell ...... atitis C: a systematic review.
@ast
Screening tests for hepatocell ...... atitis C: a systematic review.
@en
Screening tests for hepatocell ...... atitis C: a systematic review.
@nl
type
label
Screening tests for hepatocell ...... atitis C: a systematic review.
@ast
Screening tests for hepatocell ...... atitis C: a systematic review.
@en
Screening tests for hepatocell ...... atitis C: a systematic review.
@nl
prefLabel
Screening tests for hepatocell ...... atitis C: a systematic review.
@ast
Screening tests for hepatocell ...... atitis C: a systematic review.
@en
Screening tests for hepatocell ...... atitis C: a systematic review.
@nl
P2093
P2860
P356
P1433
P1476
Screening tests for hepatocell ...... atitis C: a systematic review.
@en
P2093
Eric B Bass
Geetanjali Chander
H Franklin Herlong
Kelly A Gebo
Khalil G Ghanem
Michael S Torbenson
Mollie W Jenckes
Samer S El-Kamary
P2860
P304
P356
10.1053/JHEP.2002.36817
P407
P433
P577
2002-11-01T00:00:00Z